ASX-LISTED medical life sciences company Medlab Clinical Limited has received formal "SME qualification" from the European Medicines Agency for its recently incorporated offshoot MDC Europe Limited (PD 05 Dec 2018).
The company said the registration now allows it to apply for scientific advice, drug evaluation and registration of its patented cannabis-based medicine Nanabis.
The EU registration also gives MDC Europe the opportunity for fee reductions of up to 90%, with Medlab CEO Dr Sean Hall thanking the EMA for its collaborative approach in this regard.
He said the company looked forward to escalating the Nanabis evaluation with the EMA "as we move closer to an approved drug in the EU".
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jan 19
